

TFW 1646

CASE D0028 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Audrey F. Sher
Type or print name

Audrey F. Sher
Signature

January 19, 2006
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1646

Robert J. Peach, et al.

Examiner: Ilia Ouspenski

APPLICATION NO: 09/865,321

FILED: May 23, 2001

FOR: SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF

Mail Stop **Amendment**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is submitted under 37 C.F.R. §1.97(b).

In accordance with 37 C.F.R. §1.56, Applicants wish to call the Examiner's attention to the information listed both below and on the attached form(s) PTO-1449. In accordance with 37 C.F.R. §1.56, Applicants do not include below information which Applicants believe cumulative of information already of record or herein being made of record in the application.

Applicants submit this IDS to rectify an error made in the IDS filed on October 21, 2005, as explained in the paragraph below.

Item 9 of the IDS filed on October 21, 2005 states: "As explained in the Information Disclosure Statement dated November 4, 2002, a claimed molecule was first administered intravenously to a human patient as early as November 30, 1998 in Scotland, U.K., and a claimed molecule was first administered intravenously to a human patient as early as April 24, 1999 in the United States." That statement was made in error. A claimed molecule was first administered


intravenously to a human patient as early as December 1, 1998 in Scotland, U.K., and a claimed molecule was first administered intravenously to a human patient as early as June 10, 1999 in the United States."

No representation is made that any information or document provided herein is prior art within the meaning of 35 U.S.C. § 102 or 103, and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that information or a document is not prior art.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each item of information was considered by returning a copy of the initialed PTO 1449 form(s). Applicants request that the information listed on the attached PTO 1449 form not be printed on the face of a patent. Applicants have used the PTO 1449 form(s) to provide a convenient way for the Examiner to indicate his consideration of the listed information.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3218



Audrey F. Sher
Attorney for Applicants
Reg. No. 39,024

Date: January 19, 2006



Substitute for form 1449/PTO		PTO/SB/08B (8/03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) (use as many sheets as necessary)		COMPLETE IF KNOWN			
		Application Number	09/865,321		
		Filing Date	05/23/2001		
		First Named Inventor	ROBERT PEACH		
		Art Unit	1644		
Sheet	1	of	1	Examiner Name	OUSPENSKI, ILIA
				Attorney Docket Number	D0028 NP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
		Item 9 of the IDS filed on October 21, 2005 states: "As explained in the Information Disclosure Statement dated November 4, 2002, a claimed molecule was first administered intravenously to a human patient as early as November 30, 1998 in Scotland, U.K., and a claimed molecule was first administered intravenously to a human patient as early as April 24, 1999 in the United States." That statement was made in error. A claimed molecule was first administered intravenously to a human patient as early as December 1, 1998 in Scotland, U.K., and a claimed molecule was first administered intravenously to a human patient as early as June 10, 1999 in the United States.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant